AbbVie receives orphan drug and fast track designations from the U.S. FDA for elezanumab, an investigational monoclonal antibody RGMa inhibitor, for the treatment of spinal cord injury

AbbVie

28 September 2020 - Elezanumab (ABT-555) is an investigational treatment being evaluated in neurological disorders, including treatment following spinal cord injury.

AbbVie today announced that the U.S. FDA has granted orphan drug and fast track designations for elezanumab (ABT-555), an investigational treatment for patients following spinal cord injury.

Elezanumab is a monoclonal antibody of the human immunoglobulin G1 isotype that binds selectively to repulsive guidance molecule A (RGMa). RGMa is an inhibitor of axonal outgrowth and recognised as an important factor in inhibiting neuronal regeneration and functional recovery following central nervous system damage.

Read AbbVie press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track